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ABSTRACT
Objectives We aimed to examine the relationship 
between access to medicine for cardiovascular disease 
(CVD) and major adverse cardiovascular events (MACEs) 
among people at high risk of CVD in high- income countries 
(HICs), upper and lower middle- income countries (UMICs, 
LMICs) and low- income countries (LICs) participating in the 
Prospective Urban Rural Epidemiology (PURE) study.
Methods We defined high CVD risk as the presence of 
any of the following: hypertension, coronary artery disease, 
stroke, smoker, diabetes or age >55 years. Availability 
and affordability of blood pressure lowering drugs, 
antiplatelets and statins were obtained from pharmacies. 
Participants were categorised: group 1—all three drug 
types were available and affordable, group 2—all three 
drugs were available but not affordable and group 3—all 
three drugs were not available. We used multivariable 
Cox proportional hazard models with nested clustering at 
country and community levels, adjusting for comorbidities, 
sociodemographic and economic factors.
Results Of 163 466 participants, there were 93 200 
with high CVD risk from 21 countries (mean age 54.7, 
49% female). Of these, 44.9% were from group 1, 29.4% 
from group 2 and 25.7% from group 3. Compared with 
participants from group 1, the risk of MACEs was higher 
among participants in group 2 (HR 1.19, 95% CI 1.07 to 
1.31), and among participants from group 3 (HR 1.25, 95% 
CI 1.08 to 1.50).
Conclusion Lower availability and affordability of essential 
CVD medicines were associated with higher risk of MACEs 
and mortality. Improving access to CVD medicines should 
be a key part of the strategy to lower CVD globally.
BACKGROUND
Although cardiovascular disease (CVD) 
mortality has decreased in high- income 
countries (HICs), it has remained high in 
lower- income countries (LICs) and middle- 
income countries,1 threatening the achieve-
ment of the United Nation’s Sustainable 
Development Goal 3, which includes a target 
to reduce premature mortality from non- 
communicable disease by a third by 2030.2 
Key questions
What is already known?
 ► Our previous study, using data from cross- sectional 
surveys at baseline in Prospective Urban Rural 
Epidemiology study, showed that those with cardio-
vascular disease (CVD) living in communities where 
medicines are unavailable or unaffordable are less 
likely to be on treatment or to have their blood pres-
sure controlled.
 ► However, no study has prospectively documented 
the impact of availability and affordability of CVD 
medicines on CVD outcomes.
What are the new findings?
 ► We found that essential CVD medicines were un-
available and unaffordable for a large proportion of 
communities where the individuals with a high risk 
of CVD were living, particularly in lower- middle- 
income and low- income countries.
 ► After accounting for sociodemographic and econom-
ic factors, education and comorbidities, the unavail-
ability and unaffordability of essential CVD medicines 
were associated with a higher risk of major adverse 
cardiovascular events.
 ► Our analyses are unique because we used stan-
dardised methods to assess availability, affordability 
and event rates in 21 countries and 592 urban and 
rural communities.
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Access to affordable and effective medicines has contrib-
uted to the decline in HICs, but they are either unavail-
able or unaffordable for many people living in middle- 
income countries and LICs.3 4 The WHO and World 
Heart Federation have set a goal towards achieving the 
target that at least 50% of eligible people receive drug 
therapy and counselling to prevent heart attacks and 
stroke.5
We have previously shown, using data from cross- 
sectional surveys at baseline in the Prospective Urban 
and Rural Epidemiology (PURE) study, that those with 
CVD living in communities where medicines are unavail-
able or unaffordable are less likely to be on treatment3 or 
to have their blood pressure (BP) controlled.6 However, 
no study has followed up populations in HIC, middle- 
income countries and LICs over time to quantify any 
impact of availability and affordability of CVD medicines 
on CVD outcomes. Follow- up data from PURE are now 
available, making it possible, for the first time using 
consistent methods in HICs, middle- income countries 
and LICs, to answer this question.
METHODS
Study design and participants
We analysed data from the PURE study, which has now 
recruited 192 550 participants aged 35–70 years from 23 
countries. Follow- up data are now available for 174 345 
participants from 21 countries (follow- up is still ongoing 
in the remaining participants). We included participants 
with complete follow- up data for this analysis. We also 
used the linked EPOCH (the Environmental Profile of a 
Community’s Health) data (n=1 63 466), which captures 
objective and subjective measures of environmental and 
societal factors that can influence CVD in the communi-
ties where PURE is undertaken.7 The EPOCH instrument 
comprised of two parts: EPOCH 1 is an objective environ-
mental audit tool in which trained researchers directly 
observe and systematically record physical aspects of 
the environment using a pro- forma, with standardised 
operational definitions, and EPOCH 2 is an interviewer 
administered questionnaire that captures perceptions 
about the community from PURE participants living in 
that community.
Participants were defined as having high risk of CVD 
if they had any of the following conditions: history of 
hypertension, coronary artery disease, stroke, diabetes, 
age >55, former or current smoker.8
PURE recruited participants from different HICs, 
middle- income countries and LICs, making it possible 
to investigate the impact of availability and affordability 
of CVD medicines on adverse health outcomes across 
communities at varying economic levels. The countries 
included in the PURE study represented countries in 
various stages of economic development (table 1). The 
countries were grouped based on the World Bank income 
classification in 2006 when the study was initiated. We 
recognise that a few countries changed their income 
category over the course of the study but for simplicity, 
all countries remain in their original income catego-
ries. Details of the PURE study design were described in 
previous publications.3 6 9–11
Data collection
Data on availability and costs of medicines were obtained 
using the EPOCH instrument. One community phar-
macy in each community was visited to collect informa-
tion about availability and costs of medicines.7 12 Field 
researchers were instructed to gather information for 
a list of medications and if more than one medication 
trade brand existed, to collect information about the 
most common trade name for each of these medicine 
classes as identified by the pharmacist.
As previously described, the baseline data collection 
for PURE was conducted by trained interviewers using 
standardised questionnaires to obtain information at the 
household and individual levels. At the household level, 
this included information on income and expenditure 
on food per month, and at individual level, this included 
sociodemographic information, medical history, CVD 
risk factors and medicine use.10 Medication lists were 
collected for all participant at baseline. Regular medica-
tion use was defined as taking medicine at least once per 
week in the last month. Medications were recorded by 
trained staff who were instructed to directly inspect the 
medication or prescriptions.9 Medicines were centrally 
coded into medicine classes.
Definition of essential CVD medicines
In this study, 10 medications were defined as essential 
CVD medicines: captopril, enalapril, ramipril, meto-
prolol, atenolol, amlodipine, hydrochlorothiazide, 
simvastatin, atorvastatin and aspirin.9 13 These 10 
medications were categorised into three types: (1) BP 
lowering drugs (captopril, enalapril, ramipril, metopr-
olol, atenolol, amlodipine and hydrochlorothiazide), 
(2) antiplatelets (aspirin) and (3) statins (atorvastatin 
and simvastatin).
Key questions
What do the new findings imply?
 ► These findings highlight the importance of ensuring the availability 
and affordability of essential CVD medicines globally, especially in 
LMICs. This is in line with the WHO’s ‘Global Action Plan for the 
Prevention and Control of NCDs 2013–2020’ which has a set target 
of 80% availability of affordable essential medicines for NCDs, with 
least 50% of the eligible people receiving such treatment.
 ► The study findings imply that affordability in particular is crucial in 
high, middle- income and low- income settings, and hence likely that 
without affordable access to essential cardiovascular medicines, it 
will continue to be a barrier to good medication compliance and 
cardiovascular outcomes.
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Definitions of availability and affordability of the essential 
CVD medicines
We used standardised definitions to measure availability 
and affordability. They are limited measures, and do not 
account for other factors related to access to these medi-
cations such as cost/distance to travel to pharmacies, the 
provision of free medications to some or all people in 
some communities. Medications were available if they 
were on the shelf of the pharmacy at the time of the visit, 
and cost was the price medications were sold for. We 
defined our main two exposures as follows.
Availability of essential CVD medicines was defined as the 
presence of all three types of essential CVD medications 
(BP lowering drugs, antiplatelets and statins) at any dose 
in the selected pharmacy on the day of the survey.
Affordability of essential CVD medicines was assessed using 
the total monthly costs of all three types of essential CVD 
medication types at standard doses and recommended 
frequencies.9 The lowest- cost drug in each of these three 
types of essential CVD medicine was chosen for the esti-
mation of the total monthly cost. Combined costs of the 
three types were defined as affordable if they consti-
tuted less than 20% of a household’s capacity to pay as 
per previous publications from PURE.3 6 14 Household 
capacity- to- pay is the household income remaining 
after basic subsistence needs, defined as the household 
monthly income spent on food, have been met.15
Definition of outcomes
Primary outcomes were major adverse cardiovascular 
events (MACEs)—a composite of CVD mortality, stroke, 
myocardial infarction and heart failure), and all- cause 
mortality. Participants and their family were contacted 
at regular intervals to obtain information on specific 
events. Follow- up of participants was performed at least 
every 3 years. All follow- up visits were conducted by 
Table 1 Countries included in this study with number of communities, households and participants at high cardiovascular 
risk
Number of 
communities
Number of 
households All participants
Number of participants at 
high CVD risk (% of all)
Total 592 74 281 150 185 93 200
High- income countries 113 9815 17 214 12 032
  Canada 69 6158 10 314 7461 (72.3)
  Saudi Arabia 18 636 1494 760 (50.9)
  Sweden 23 2372 3907 3011 (77.1)
  United Arab Emirates 3 649 1499 800 (53.4)
Upper middle- income countries 117 21 440 39 180 27 189
  Argentina 20 4305 7509 5558 (74.0)
  Brazil 14 3636 6079 4625 (76.1)
  Chile 5 1934 3521 2634 (74.8)
  Malaysia 28 6525 12 954 7901 (61.0)
  Poland 4 1294 2031 1662 (81.8)
  South Africa 8 1658 3029 1906 (62.9)
  Turkey 38 2088 4057 2903 (71.6)
Lower middle- income countries 207 28 142 59 737 35 458
  Colombia 55 3685 6896 4360 (63.2)
  China 93 19 738 42 861 25 533 (59.6)
  Iran 20 2400 6013 2904 (48.3)
  Palestine 35 1055 1574 1058 (67.2)
  Philippines 4 1264 2393 1603 (67.0)
Low- income countries 68 3543 7791 18 521
  Bangladesh 55 1174 2926 1410 (48.2)
  Pakistan 4 838 1713 1161 (67.8)
  Tanzania 6 818 1910 847 (44.3)
  Zimbabwe 3 713 1242 808 (65.1)
  India 87 11 341 26 263 14 295 (54.4%)
High risk of CVD was defined as having any of the following conditions: history of hypertension, coronary artery disease, stroke, diabetes, 
age >55, former or current smoker.
CD, cardiovascular disease.
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visiting households, by telephone calls or by inviting the 
participants to the central research offices to complete 
the follow- up visit. Events were characterised centrally in 
each country by trained physicians, using standardised 
definitions, verbal autopsies and review of documents.11
Statistical analysis
All statistical analyses were performed with SAS V.9.4 and 
R. Continuous variables were presented as mean (SD or 
median, range), and categorical variables as frequency 
and percentage. Data were, in some instances, presented 
as groups by overall country economic status for ease of 
presentation, however it is acknowledged that socioeco-
nomic heterogeneity exists within many countries also. 
Models hence account for household and individual- 
level socioeconomic measures.
We examined the combination of availability and 
affordability through a combined variable. Participants 
were classified into three groups according to the avail-
ability and affordability of the three types of medications 
(BP lowering, statin and antiplatelets): group 1—indi-
viduals from communities where all three were available 
and affordable, group 2—individuals from communities 
where all three were available but not affordable to them 
and group 3—individuals from communities where all 
three were not available. Group 1 was used as the refer-
ence group. We also performed additional analysis on 
the association between the number of essential CVD 
medicines available and MACEs.
Multilevel Cox proportional hazard models that 
account for nested clustering at country and community 
levels were applied to calculate the HRs and their 95% 
CIs for MACEs and all- cause mortality. The clustering was 
incorporated using a frailty model, which involves intro-
ducing a shared random effect into the proportional 
hazard model for participants from the same cluster.16 
Nesting of community within country was incorporated 
by nesting the community random effect within the 
country random effect. We adjusted for covariates as in 
previous publications from the PURE study, including 
age, gender, educational level, smoking status, history of 
hypertension, coronary heart disease, stroke, diabetes, 
number of people in household, rural/urban living and 
the Global Wealth Index country specific tertiles.6 The 
Wealth index was created using information collected on 
the household possessions from the PURE baseline ques-
tionnaire. Items included electricity, car, computer, tele-
vision, motorbike, livestock, fridge, other four- wheeler 
vehicle, washing machine, stereo, bike, kitchen mixture, 
phone, land and kitchen window. Binary classification of 
yes/no was created for each item and then a principal 
component analysis was used to extract the compo-
nent with largest eigenvalue. Each household was then 
assigned to a score based on factor loadings.
Data from India were presented separately from other 
LICs to be consistent with previous publications from 
the PURE study. India was seen to be very different 
from all of the other LICs with respect to availability of 
cardiovascular medicines due to the large domestic phar-
maceutical industry and the practice that many medicines 
are available over the counter and without prescription, 
as well as to particular policies, such as selective process 
controls.3 14
Patient and public involvement
Patients or the public were not involved in the design, 
or conduct, or reporting or dissemination plans of our 
research.
RESULTS
There were 163 466 adults with follow- up data in the 
PURE database at the time of analysis (August 2019) 
and among these 93 200 adults were defined as having 
high risk of CVD, from 592 communities and 21 coun-
tries (table 1). Among those identified as high risk, 39 
968 (42.9%) had two or more risk factors, and 53 232 
(57.1%) had only one single factor among the defined 
risk factors.
The mean age was 54.7 years, 49.0% were female. Base-
line characteristics of these participants are presented in 
table 2. Participants from communities with no medica-
tions available had the highest prevalence of poor educa-
tion, low wealth index, rural living and had lower use of 
preventative medications at baseline (table 2).
The percentages of individuals with high CVD risk 
from communities where all three types of CVD medi-
cines were available were 74.3% overall, 97.0% in HICs, 
85.2% in UMICs, 57.8% in LMICs, 24.1% in LICs and 
88.3% in India. The percentages of high CVD risk indi-
viduals from communities where all three types of CVD 
medicines were available and affordable (group 1) was 
44.9% overall, 94.8% in HICs, 57.2% in UMICs, 28.6% 
in LMICs, 10.1% in LICs and 29.9% in India (figure 1).
Overall, BP lowering medication had the highest rate 
of availability (95.1% of the communities), followed by 
antiplatelets (92.9%), and 78.5% for statins. The avail-
ability of these three types of essential CVD medicines 
was consistently lower in LICs compared with countries 
with higher income, particularly for statins (except for 
India, where medicines were relatively widely available) 
(online supplemental table S1 and S2).
After 9 years of follow- up in this high- risk population, 
the incidence of MACEs was 6.74% (2482/36330) in 
participants in group 1 (age standardised rate 6.83%), 
8.67% (1825/21065) in participants in group 2 (age 
standardised rate 8.63%) and 7.99% (1583/19810) in 
participants in group 3 (age standardised rate 8.06%). 
Using group 1 as the reference group, the risk of MACEs 
was greater in group 2 (all three types of CVD medicines 
were available but not affordable), with the adjusted 
HR=1.19, 95% CI 1.07 to 1.31, p<0.001 and in group 3 
(all three types of CVD medicines were not available), 
with the adjusted HR=1.27, 95% CI 1.08 to 1.50, p=0.004. 
(figure 2)
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The all- cause mortality rate was 8.88% (8210/92435) 
in all high- risk participants. It was higher, at 12.64% in 
group 2 (age standardised rate 12.52%), and at 9.45% 
in group 3 (age standardised rate 9.50%), compared 
with 5.84% in group 1 (age standardised rate 5.99%). In 
Cox proportional hazard models with participants from 
group 1 (all three types of CVD medicines were available 
and affordable) as the reference group, the risk of all- 
cause mortality was also greater with both lack of avail-
ability and/or affordability. Compared with group 1, the 
risk of all- cause mortality was greater in group 2, with the 
adjusted HR=1.20, 95% CI 1.08 to 1.32, p<0.001 and in 
group 3, with the adjusted HR=1.25, 95% CI 1.04 to 1.50, 
p=0.015 (figure 3).
The percentages (95% CI) of MACEs and mortality 
by availability and affordability during follow- up are 
presented in online supplemental appendix table S3. 
Unadjusted HRs for MACEs and all- cause mortality by 
availability and affordability are shown in online supple-
mental appendix table S4.
Similar results were found through sensitivity anal-
yses using different age thresholds (>60 or>65, online 
Table 2 Baseline characteristics of participants with high risk of CVD
Total high risk 
participants
n=93 200
Group 1—available 
and affordable
n=34 974
Group 2—
available but 
unaffordable
n=22 918
Group 3—
unavailable
n=20 022
Missing
n=15 286
Age (years), median (SD), missing: 2 54.7 (9.6) 54.4 (9.3) 54.9 (9.7) 54.5 (9.7) 55.2 (9.7)
Female, n (%), missing: 1 45 700 (49.0%) 16 621 (47.5%) 11 419 (49.8%) 9423 (47.1%) 8237 (53.9%)
Educational level, n (%), missing: 261
  None 13 924 (15.0%) 2542 (7.3%) 4136 (18.1%) 4679 (23.5%) 2567 (16.8%)
  Primary school 27 909 (30.0%) 7318 (20.9%) 7639 (33.5%) 7214 (36.2%) 5738 (37.6%)
  Secondary/high school 32 637 (35.1%) 12 661 (36.2%) 9029 (39.6%) 6536 (32.8%) 4411 (28.9%)
  Trade school 4432 (4.8%) 2536 (7.3%) 690 (3.0%) 589 (3.0%) 617 (4.0%)
  College/university 13 740 (14.8%) 9733 (27.9%) 1269 (5.6%) 850 (4.3%) 1888 (12.4%)
  Unknown 297 (0.3%) 147 (0.4%) 44 (0.2%) 84 (0.4%) 22 (0.1%)
Global Wealth Index country specific tertiles, missing: 188
  Tertile 1 30 357 (32.6%) 7499 (21.4%) 8099 (35.4%) 9493 (47.5%) 5266 (34.8%)
  Tertile 2 30 676 (33.0%) 11 091 (31.7%) 7963 (34.8%) 6477 (32.4%) 5145 (34.0%)
  Tertile 3 31 979 (34.4%) 16 378 (46.8%) 6847 (29.9%) 4013 (20.1%) 4741 (31.3%)
Smoking status, n (%), missing: 723
  Former smoker 17 156 (18.6%) 9100 (26.1%) 2669 (11.8%) 2232 (11.3%) 3155 (20.8%)
  Current smoker 30 926 (33.4%) 9695 (27.8%) 8503 (37.5%) 7743 (39.2%) 4985 (32.8%)
  Never smoke 44 395 (48.0%) 16 044 (46.1%) 11 525 (50.8%) 9767 (49.5%) 7059 (46.4%)
Number of people in the household, 
median (Q1, Q3) missing: 11 386
3.0 (2.0–4.0) 3.0 (2.0–5.0) 4.0 (2.0–5.0) 3.0 (2.0–5.0) 3.0 (2.0–5.0)
Urban/rural living, n (%), missing: 0
  Urban 53 151 (57.0%) 26 163 (74.8%) 13 208 (57.6%) 5623 (28.1%) 8157 (53.4%)
  Rural 40 049 (43.0%) 8811 (25.2%) 9710 (42.4%) 14 399 (71.9%) 7129 (46.6%)
History of hypertension, n (%), missing: 
205
31 546 (33.9%) 12 638 (36.2%) 7592 (33.2%) 5869 (29.4%) 5447 (35.7%)
History of diabetes, n (%), missing: 159 12 522 (13.5%) 5524 (15.8%) 3182 (13.9%) 1847 (9.3%) 1969 (12.9%)
History of coronary heart disease, n (%), 
missing: 172
5774 (6.2%) 2267 (6.5%) 1219 (5.3%) 1401 (7.0%) 887 (5.8%)
History of stroke, n (%), missing: 179 2547 (2.7%) 847 (2.4%) 632 (2.8%) 644 (3.2%) 424 (2.8%)
Use of preventative medication:
  Antiplatelets 6037 (6.5%) 3114 (8.9%) 861 (3.8%) 836 (4.2%) 1226 (8.0%)
  Statins 4761 (5.1%) 3189 (9.1%) 508 (2.2%) 239 (1.2%) 825 (5.4%)
  BP lowering 20 852 (22.4%) 9517 (27.2%) 4174 (18.2%) 2967 (14.8%) 4194 (27.4%)
Group 1—individuals from communities where all three were available and affordable, group 2—individuals from communities where all three 
were available but not affordable to them, group 3—individuals from communities where all three were not available.
High risk of CVD was defined as having any of the following conditions: history of hypertension, coronary artery disease, stroke, diabetes, 
age >55, former or current smoker.
All p- values for differences between groups were <0.001
BP, blood pressure; CVD, cardiovascular disease.
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supplemental appendix table S5 and S6), different 
thresholds for capacity to pay (10% or 25%, online 
supplemental appendix tables S7‒S9) and different defi-
nition of high risk individual (the non- laboratory INTER-
HEART risk score,17 online supplemental appendix 
tables S10‒S13).
The number of medicines available among the 10 
studied medications varied considerably (online supple-
mental appendix figure S1). For each additional drug 
available, the hazard of MACEs reduced by 5% (95% CI 
0.93 to 0.98, p<0.001) (online supplemental appendix 
figure S2).
Affordability was a key factor across countries from 
all income categories. For people living in HICs, the 
impact of affordability on MACEs appeared even higher 
compared with those living in middle- income countries 
and LICs. Online supplemental appendix figure S3 pres-
ents the adjusted HRs of affordability (not affordable vs 
affordable) on time to MACEs for each economic group.
DISCUSSION
In this study, we found that essential CVD medicines were 
unavailable and unaffordable for a large proportion of 
communities where the individuals with high risk of CVD 
were living, particularly in LMICs and LICs. The unavaila-
bility and unaffordability of essential CVD medicines was 
associated with increased risk of MACEs after accounting 
Figure 1 Percentages of individuals with high CVD risk from communities where three types of CVD medicines are available 
(left) and affordable (right). CVD, cardiovascular disease; HIC, high- income countries; LICs, low- income countries; LMICs, lower 
middle- income countries; UMICs, upper middle- income countries.
Figure 2 Availability and affordability of three types of 
CVD medicines and MACEs (group 1 was the reference 
group). CVD, cardiovascular disease; MACE, major adverse 
cardiovascular events.
Figure 3 Availability and affordability of three types of CVD 
medicines and mortality (group 1 was the reference group). 
CVD, cardiovascular disease.
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for sociodemographic and economic factors, education, 
comorbidities and accounting for clustering.
Low availability and affordability to cardiovascular 
medicines in LICs and middle- income countries have 
been reported in several studies. In a study published in 
2010, van Mourik et al found that the overall availability 
of cardiovascular medicines in 36 countries at all levels 
of development was poor (26.3% in public sector, 57.3% 
private sector) and cardiovascular medicines were least 
affordable in the poorest countries.18 In a survey of avail-
ability and affordability of selected essential medicines 
for chronic diseases in LICs and middle- income coun-
tries conducted by Mendis et al in 2007, the availability 
of some essential CVD medicines was extremely low in 
some countries (eg, hydrochlorothiazide: 0.7% in Paki-
stan, 5.8% in Bangladesh; captopril: 0.5% in Nepal, 5.6% 
in Malawi; enalapril: 0.8% in Malawi; and statin: ranged 
from 0.1% to 21% in the all the surveyed countries), and 
the affordability of these medicines was also poor.4 In 
another study of hypertension management in 44 LICs 
and middle- income countries, only 29.9% of people 
with hypertension received antihypertensive treatment, 
and in only 10.3% was it controlled.19 In a recent study 
conducted by Husain et al based on the WHO online 
repository of national essential medicines lists for 53 
countries, the average availability of the essential CVD 
medications was 54% in LICs and lower- middle- income 
countries (LMICs) and 60% in HICs and upper- middle- 
income countries (UMICs).20 They also found that 
affordability was lower in LICs and LMICs than HICs and 
UMICs for both brand and generic medications.20 In our 
previous publications from the PURE study, overall hyper-
tension control was worst in LICs and LMICs (10.8%), 
with poor access to medicines among the reasons for the 
low frequency of treatment and control of hypertension 
in these countries.6 21 The data in the majority of these 
studies are now dated, we need repeat assessments to 
track medication availability and affordability as these 
could change over time.
Interestingly, in contrast to our anticipation, the 
crude rates of MACEs and all- cause mortality were actu-
ally higher in group 2 compared with group 3. Group 2 
comprised of participants with high risk of CVD that lived 
in communities where essential CVD medicines were 
available but unaffordable to them. This may be due to 
the higher prevalence of comorbidities such as hyperten-
sion and diabetes in this group. In addition, the propor-
tion of urban living was also higher in group 2 compared 
with group 3 (57.6% vs 28.1%, respectively). Urban living 
may be associated with other factors that can increase 
the risk of MACEs and all- cause mortality such as anxiety, 
depression, sedentary lifestyle, high consumption of fast 
food and diseases related to air pollution, especially in 
LICs and middle- income countries. This finding may also 
highlight the fact that affordability was a key factor. Even 
when the medications are available in the communities, 
people still could not access them if they could not afford 
them. In this study, the impact of affordability on MACEs 
in people living in HICs was even higher compared with 
those living in LICs and middle- income countries, as 
shown in the online supplemental appendix figure S3.
Strengths
Our analyses are unique because we used standardised 
methods to assess availability, affordability and event rates 
of MACEs and all- cause mortality from 21 countries and 
592 urban and rural communities worldwide.
Our results support previous findings that in LICs and 
middle- income countries, the availability and afford-
ability of key medicines for the prevention of CVD are 
low and provide evidence that this affected adversely on 
outcomes in populations at risk of CVD.
Limitations
As noted in previous publications from the PURE study, 
our results capture only part of the costs of treatment,3 
as we are unable to take into account other costs (such 
as professional fees or travel or time taken of work to visit 
a doctor) and hence, we could have overestimated its 
affordability. In addition, we were also unable to account 
for policies and other activities of non- governmental organ-
isations in various regions of the world that may provide 
free medications to some participants in some countries, 
which may influence medication use and access to variable 
degrees. We do not have information about how household 
incomes might have changed during follow- up, which may 
be important given the economic impact of illness. Also, 
availability and affordability were only assessed at base-
line (but this is inevitable in such a large study in which 
we aimed to relate these to long- term outcomes) and may 
have changed over time. Moreover, during the study time, 
several countries transitioned to other income categories, 
for example, India: LIC–LMIC (2009), China: LMIC–
UMIC (2013), Colombia: LMIC–UMIC (2008), Iran: 
LMIC–UMIC (2010). Along with these transitions, their 
health systems may have changed as well. The availability 
and affordability of medicines were assessed at the commu-
nity pharmacy level, therefore it may not necessarily reflect 
the availability and affordability at different points of care 
such as pharmacies at public health facilities or private 
health facilities. The criteria that EPOCH used to collect 
medicine price entailed surveying the most common trade 
name for each of these medicine classes identified by the 
pharmacists. While our method attempted to identify the 
most available medicine in the pharmacy and its cost, there 
is variation in availability and price particularly between 
generic and brand drugs across pharmacies. Availability of 
a particular CVD medicine may also depend whether the 
country Essential Medicine Lists include the medicines 
in the first place. In addition, there may be other aspects 
of access to healthcare that may have changed, such as 
number of health workers, availability of diagnostic and 
therapeutic interventions and we do not have data on 
these. The criteria used to define high risk patients resulted 
in having a mixed group of patients that are not at the same 
level of risk. For the various reasons described above, the 
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HRs calculated in these analyses could be underestimated 
compared to an analysis in which availability and afforda-
bility was more more accurately measured.
Implications for practice/policy
The medicines studied in this paper have been shown to 
be effective in primary and secondary prevention of CVD 
events and to reduce mortality, and are recommended in 
most clinical guidelines but were unavailable in a large 
proportion of communities in LICs and middle- income 
countries and even when available they were not always 
affordable. In a previous publication from the PURE study, 
both low availability and affordability were associated with 
low use of CVD medicines.3 This points to a plausible expla-
nation of the association with MACEs and mortality.
According to the WHO, essential medicines are those 
that satisfy the priority healthcare needs of the popula-
tion.22 Essential medicines should be available within 
functioning health systems at all times, in adequate 
amounts, in the appropriate dosage, with assured quality 
and at an affordable price to individuals and communi-
ties.22 The WHO’s Global Action Plan set a target of 80% 
availability of affordable essential medicines for non- 
communicable diseases worldwide, and at least 50% of 
those in need of these medicines by 2025.23 This requires 
addressing the most common reasons for medicines 
shortages, catalogued in a review conducted by Acosta 
et al.24 These include market- related factors (such as 
increased demand, voluntary withdrawal, unexpected 
changes in clinical practice, loss of market interest and 
relocation of production facilities), supply chain manage-
ment (structure of the network or supply chain in the 
country, supply of raw materials and excipients), manu-
facturing processes (quality concerns, changes in the 
product formulation, industrial development capacities, 
production problems), reduced public health funding, 
political and ethical issues (such as regulatory problems, 
public policy and social conflicts). In LICs and middle- 
income countries, the rising prices of medicines, often 
paid out- of- pocket, mean that they account for up to 70% 
of total healthcare expenditure24 and can lead to illness- 
induced poverty and reduce access to the needed treat-
ment. More research effort and strategies are needed to 
improve affordability to essential medicines. In a recent 
publication from the Heart Outcomes Prevention and 
Evaluation 4 (HOPE-4) study in individuals with new or 
poorly controlled hypertension from 30 communities in 
Colombia and Malaysia, free distribution of a fixed dose 
combination of two antihypertensive drugs and statins 
substantially improved the Framingham risk score and 
improved the control of hypertension and low- density 
lipoprotein (LDL) cholesterol in the participants.25 
Ensuring access to essential medicine plays a major role 
in the prevention and control of CVD, which is both 
important to prevent long- term adverse outcomes and 
also essential during the current COVID-19 pandemic 
situation. According to a recent review, the presence of 
pre- existing CVD was consistently associated with signifi-
cantly worse outcome in patients with COVID-19.26
CONCLUSIONS
Less availability and affordability of essential CVD medi-
cines were associated with increased risk of MACE and 
all- cause mortality in this global population from coun-
tries of varying income levels. These findings highlight the 
importance of ensuring that essential CVD medicines are 
available and affordable for those at high risk of CVD every-
where. Factors associated with availability and affordability 
of essential CVD medicines must be identified for appro-
priate care globally.
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